Insider · CIK 0001477037
Cuong Do V
Files at BIVI (BIOVIE INC.). First filing -, latest -.
Cuong Do V files SEC Form 4 as CEO, president and director at BIVI (BIOVIE INC.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Cuong Do V has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 5, 2026 | BIVI BIOVIE INC. | AGrant or award Stock Option (right to buy)derivativeindirect: See Footnote | +665,300 | $0.00 | $0 | 665,300 | Jan 9, 2026 |
| Aug 7, 2025 | BIVI BIOVIE INC. | POpen-market purchase Common Stockindirect: See Footnote | +5,000 | - | - | 9,992 | Aug 13, 2025 |
| Aug 7, 2025 | BIVI BIOVIE INC. | POpen-market purchase Warrants (right to buy)derivativeindirect: See Footnote | +5,000 | - | - | 5,050 | Aug 13, 2025 |
| Dec 20, 2024 | BIVI BIOVIE INC. | AGrant or award Stock Option (right to buy)derivativeindirect: See Footnote | +104,502 | $0.00 | $0 | 104,502 | Jan 7, 2025 |
Questions about Cuong Do V
Answered from the filings on this page, as of the latest one.
Is Cuong Do V buying or selling?
Cuong Do V has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Cuong Do V's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Cuong Do V has 0.
Where does Cuong Do V file Form 4?
Cuong Do V has filed Form 4 at BIVI (BIOVIE INC.) as President & CEO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.